RCM
ABEO icon

Rotella Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Rotella Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-852
Closed -$108K – 530
2015
Q2 		$108K Buy
+852
New +$128K 0.09% 262

Other funds holding ABEO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Rotella Capital Management's ABEO Position: Q3 2015 in Review

Rotella Capital Management sold out of Abeona Therapeutics (ABEO) in Q3 2015, closing a stake of 852 shares — an estimated $108K sold.

Rotella Capital Management first reported a position in ABEO in Q2 2015 and held it in 1 quarter. The position peaked at $108K in Q2 2015. 43 funds tracked by Wall St. Rank hold ABEO as of Q3 2015.

  • Rotella Capital Management reported no remaining Abeona Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Rotella Capital Management sold 852 Abeona Therapeutics shares in Q3 2015, an estimated $108K.
  • Rotella Capital Management first reported a position in Abeona Therapeutics in Q2 2015 and held it in 1 quarter.
  • Rotella Capital Management's Abeona Therapeutics position peaked at $108K in Q2 2015.
  • 43 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2015.

Based on Rotella Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.